Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nobelpharma
Nobelpharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Hyftor
Sirolimus
2022-03-22
2029-2040
Kidney transplantation
,
Graft rejection
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Sirolimus
therapeutic equivalency
,
tuberous sclerosis
,
sclerosis
,
angiofibroma
,
neurofibromatosis 1
,
neurofibromatoses
,
neurofibroma
ME-344
duchenne muscular dystrophy
,
muscular dystrophies
Antithrombin iii
glioma
Ademetionine
endometriosis
,
dysmenorrhea
,
muscular diseases
,
acrocephalosyndactylia
,
distal myopathies
Regramostim
covid-19
Molgramostim
covid-19
ARBEKACIN
duchenne muscular dystrophy
,
muscular dystrophies
Sodium chloride
cytomegalovirus infections
,
neuralgia
,
tympanic membrane perforation
,
acute pain
,
herpes zoster
,
herpes simplex
,
covid-19
Sodium lactate
healthy volunteers/patients
Aspartame
premature birth
,
apnea
Microcrystalline cellulose
healthy volunteers/patients
Sagramostim
covid-19
Tisseel
tympanic membrane perforation
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use